Distinguished Lecturer Seminar Series
Prof. Richard Vile - Mayo Clinic
Date: 27.11.2025
Time: 11:00
Location: Main Auditorium
Hosts: D. Nettelbeck, G. Ungerechts, M. Leber
Titel: "Oncolytic Viruses as Lymphoeditors in Cancer Immunotherapy"
About:
Richard Vile, Ph.D., and his research team develop experimental cancer therapies, all based on stimulating antitumor immune responses.
Dr. Vile's research combines in vivo and in vitro assays, but predominantly focuses in murine immune-competent models and syngeneic tumors. Although his team has a major interest in melanoma, they also have models of prostate cancer, glioma and brain metastases, and can be applied across tumor sites. Dr. Vile’s research focus areas: Oncolytic viruses (OV) have been one of Dr. Vile's key areas of research for several years, and his team previously demonstrated the critical role of the immune system in successful therapy with OV. In addition to making OV expressing cytokines and tumor-associated antigens, they have developed a novel approach in which the vesicular stomatitis virus (VSV) can be engineered to express a library of tumor antigens, resulting in exceptional treatment. Adoptive cell therapy (ACT) is one of few treatments shown to be effective for patients with melanoma. In preclinical models, Dr. Vile's team demonstrated that combining ACT with OV can improve its effectiveness.
All of this work is intended to help patients with cancer. Dr. Vile's team deliberately focuses on developing therapies that can be rapidly taken to clinical trials. Accordingly, the team works closely with the Mayo Clinic team, as well as those at other U.S. hospitals and worldwide, and have been directly involved in clinical trials of several oncolytic viruses.
An ongoing clinical trial for patients with hepatocellular carcinoma is being performed at Mayo Clinic in Arizona with a VSV the team designed to express interferon. Internationally, Dr. Vile's research lab has strong links with researchers in the UK and other countries, to test OV in patients with a range of cancers.
DDLSS Committee Members
-
Dr. Michael Milsom
Head of DDLSS Committee
- Show profile
Prof. Dr. Aurelio Teleman
-
Prof. Dr. Klaus Maier-Hein
Head of Division
-
Prof. Dr. Darjus Felix Tschaharganeh
- Show profile
Prof. Dr. Hedda Wardemann
Division Head
-
Prof. Dr. Mathias Heikenwälder
- Show profile
Prof. Dr. Volker Arndt
Head
-
Prof. Dr. Claudia Scholl
- Show profile
Prof. Dr. Christoph Plass
Division Head
-
Prof. Dr. Christiane Opitz
- Show profile
Prof. Dr. Leif Schröder
Abteilungsleitung Translationale Molekulare Bildgebung
-
Dr. Gislene Pereira
-
Priv. Doz. Dr. Titus Brinker
Abteilungsleitung
